When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MYOV - Myovant Sciences presents positive efficacy data of phase 3 HERO study at ASCO20 with simultaneous publication in NEJM
Myovant Sciences Ltd.
Myovant Sciences (MYOV) announced additional results from its Phase 3 HERO study of once-daily, oral relugolix in men with advanced prostate cancer in an oral presentation at the ASCO20 Virtual Scientific Program.
More news on: Myovant Sciences Ltd., Healthcare stocks news,